Tag: NASDAQ: DMPI

April 30, 2018

8 Glioblastoma Treatment Stocks

With an average survival rate of 16 months, glioblastoma is the most common and deadly type of brain cancer, accounting...
April 10, 2018

Investing in Glioblastoma Treatments

Glioblastoma tumors are one of the most aggressive forms of cancer and yet have very few treatments. Here's how investing...
December 26, 2017

DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new...
November 21, 2017

DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today provided...
November 14, 2017

DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) has announced financial results for Q1 ended September 30, 2017. The Company also announced a business...
November 7, 2017

DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer

DelMar Pharmaceuticals, Inc. (Nasdaq:DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today...
October 31, 2017

DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer

DelMar Pharmaceuticals, Inc. (Nasdaq:DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today...
October 10, 2017

SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)

SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public...
October 3, 2017

DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of a...
September 29, 2017

DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced its financial results...